Home > Boards > US Listed > Biotechs >

Aptose Biosciences, Inc. (APTO)

Add APTO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/3/2019 11:24:45 AM - Followers: 15 - Board type: Free - Posts Today: 0

Lorus Therapeutics Implements Name Change to Aptose Biosciences


Business Information:

Aptose Biosciences. Inc.
Ticker: APTO
PPS: 1.64    a/o     7/13/2017
Up 0.12 points or 7.89%
Market Value: $23,895,510 a/o July 12, 2017
Outstanding Shares: 15,721,388 a/o Dec 31, 2016
APTOSE Website: http://aptose.com/

Fundamental analysis:

According to Aptoses’ website, Aptose Biosciences is a biotechnical company that looks to find treatments for cancers. These cancers include acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies.
From their research, they have discovered that “CG026806 (CG’806) is a highly potent first-in-class pan-FLT3/BTK inhibitor.” This knowledge is aiding their fight against chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), large B cell lymphoma (DLBCL), and more. Aptose also has another program called APTO-253 which is also aiding to treat cancer.
Aptose Management:
William G. Rice, Ph.D.  Chief Executive Officer (CEO)
Daniel D. Von Hoff, M.D., F.A.C.P. Senior Vice President, Medical Affairs
Stephen B. Howell, M.D. Acting Chief Medical Officer
Avanish Vellanki Chief Business Officer (CBO)
Gregory Chow Chief Financial Officer (CFO)                  
Institutional Ownership 11.11 %
Total Institutional Shares: 2,417,492
NASDAQ APTO Institutional Ownership Link
No Insider Traders
Possible Float: ~13,303,896
Looking at Aptoses’ income statement, they have a running loss with $0 in revenue. For the first quarter of 2017, the company had a net loss of ~$4,355,000. Also, over the course of the last year, the company has had a net loss of ~$17,910,000. Unless the company can create and sell one of their cures, Aptose will continue to run at a loss. If the company was to sell one of their cures, it comes down to how effective and efficient the drug is. These medicines would help it penetrate a full cancer treatments market. There is the possibility that the drugs and treatments could sell very well, but there is serious doubt that such an event will happen.
Aptoses’ balance statement shows that it has ~11,958,000 in on hand cash Q1 2017. From what we were able to find, the company is gaining on-hand cash from selling company shares to investors. In total, Aptose has a total of ~$12,676,000 in assets for Q1 2017. For accounts payable, Aptose has ~$2,340,000 in current liabilities. For shareholders equity, investors of Aptose have ~$235,869,000 in shares. The accumulated deficit for investors is ~$247,877,000.
On 6/8/2017, the company got rated as neutral by Rodman & Renshaw. Also, analysts rated the stock as a buy with a price target of $9. In forward-looking thoughts, $9 is a very optimistic number to put on a stock that currently doesn’t have any income, and is relying solely on investors. Our forward-looking though suggests that the stock will continue its period of consolidation until either they run out of funds or release a new product. Depending on the event, the price per share will reflect the positive or negative aspects of that event.
On 6/6/2017, the company held an annual meeting of shareholders. During this press release, the voting results for the company’s board of directors were released. Also, the company told shareholders that they displayed CG’806 in a presentation last month in Boston. From the press release, they stated that the product/treatment was performing well during their tests.

http://www.greenpennystocks.net/2017/08/aptose-biosciences-inc-forward-looking.html" rel="nofollow">Read More Here

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
APTO News: Current Report Filing (8-k) 05/16/2019 10:17:09 AM
APTO News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 05/13/2019 06:09:01 AM
APTO News: Current Report Filing (8-k) 05/13/2019 06:03:22 AM
APTO News: Current Report Filing (8-k) 05/13/2019 06:02:34 AM
APTO News: Proxy Statement (definitive) (def 14a) 05/08/2019 04:35:17 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#118   Does anyone have a clue why APTO had mte1955 04/03/19 11:24:45 AM
#117   So I guess April 1 was no big deal? mte1955 04/02/19 10:38:17 AM
#116   $APTO SELL Book Value Per Share (mrq) $0.40 SlaptheSwing 03/18/19 02:31:50 PM
#115   On my radar for April 1, presentations. crudeoil24 03/01/19 08:03:53 AM
#114   APTO NEWS https://finance.yahoo.com/news/aptose-present-cg-806-apto-120000921.html [SMART MONEY] 03/01/19 07:27:48 AM
#113   Gap filled Gtrading 10/09/18 04:06:17 PM
#112   Considering its performance over the past week, what mte1955 10/09/18 11:08:51 AM
#111   Looks like it wants to fill that last gap Gtrading 10/08/18 06:01:27 PM
#110   8-10 pps by end of year very possible! Bangtime 07/04/18 06:04:22 AM
#109   APTO:Added on-the US-side today on-that sma50 test Sibware 07/02/18 03:12:16 PM
#108   meanwhile it close up less than 4% [SMART MONEY] 06/30/18 07:29:21 PM
#107   Aptose Says FDA Lifts Clinical Hold on Cancer crudeoil24 06/29/18 08:55:56 AM
#106   I grabbed about 3k avg 4.39 [SMART MONEY] 06/29/18 08:03:51 AM
#105   Long term uptrend! crudeoil24 06/29/18 08:00:47 AM
#104   “We are eager to return APTO-253 back into [SMART MONEY] 06/29/18 07:56:50 AM
#103   Strictly a back test of the highs previously Bangtime 06/17/18 06:12:50 AM
#102   Looks like folks selling their shares they have crudeoil24 06/14/18 08:06:42 AM
#101   Nice news, got some early momo. APTO crudeoil24 06/14/18 07:46:09 AM
#100   Great news today for their drug, 806. Bangtime 06/14/18 07:14:30 AM
#99   Breakthrough to new high Gtrading 06/08/18 10:09:00 AM
#98   Moving towards the removal of the FDA hold tjguy 03/01/18 08:12:50 AM
#97   APTO buy 2.77 stocktrademan 02/11/18 01:00:57 PM
#96   Gap filled Gtrading 02/06/18 10:55:33 AM
#95   Next stop should be 2.50 ish. Time will tell Gtrading 01/30/18 11:52:14 AM
#94   bott in agen--betar not roll bk ernie44 01/27/18 10:28:14 AM
#93   All out here. Gonna see if we fill Gtrading 01/26/18 11:17:06 AM
#92   Good opportunity to average up Gtrading 01/25/18 01:14:51 PM
#91   fell back to allow a breather ernie44 01/25/18 12:27:20 PM
#90   So far it’s been stellar. As they say...weeeeeee Gtrading 01/24/18 04:44:17 PM
#89   this could be the best run in 10 years ernie44 01/24/18 01:58:33 PM
#88   That would be an amazing number. Well we Gtrading 01/24/18 01:02:38 PM
#87   MY need is 40 ..by xmas ernie44 01/23/18 11:45:01 PM
#86   Geeesh...at this rate we may $4 by Friday Gtrading 01/23/18 05:42:16 PM
#85   not concern --its a habit with them---skimming is ernie44 01/23/18 10:30:51 AM
#84   Nice steady rise. Love it. It’s been a Gtrading 01/22/18 06:01:42 PM
#83   not YET.........ONLY HALF WAY THERE ernie44 01/22/18 02:02:16 PM
#82   And a huge move after hours Gtrading 01/19/18 04:14:42 PM
#81   And higher. Looks like a gap open Gtrading 01/16/18 08:47:26 AM
#80   Quietly moving higher and higher Gtrading 01/12/18 12:42:03 PM
#79   .20 move is nothing lol starkd748 12/27/17 12:31:47 PM
#78   * * $APTO Video Chart 12-26-17 * * ClayTrader 12/26/17 05:22:53 PM
#77   NICE BUMP ---BUBBA DOC. ernie44 12/26/17 11:40:22 AM
#76   Looks great to keep ripping. +$$ Leezee Life Strategies 12/26/17 10:51:20 AM
#75   shorts begin to bleed Insurge64 12/26/17 10:04:25 AM
#74   APTO Search Orphan Drug Designations and Approvals Insurge64 12/26/17 09:45:06 AM
#73   whats not to like---now i know to stay ernie44 12/17/17 12:47:14 PM
#71   3 year high decended to 8, then ernie44 12/07/17 04:18:15 PM
#70   When are you going to call a stockmoneybaby 11/13/17 06:50:13 PM
#69   * * $APTO Video Chart 11-13-17 * * ClayTrader 11/13/17 05:22:27 PM
#68   Aptose Biosciences. Inc. Forward-Looking Analysis Decatsmeow 08/10/17 04:27:59 AM